Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
GlobalNewswire
27 April 2022
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html
Statera Biopharma, a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced an agreement with Immune Therapeutics to sell Statera’s rights to any product containing met-enkephalin or low-dose naltrexone as an active ingredient.
Immune Therapeutics is a specialty pharmaceutical company involved in manufacturing, distribution and marketing of novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system.
Statera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.